Background: Colo-rectal cancer (CRC) is the third most frequent cancer in the world, and the fourth greatest cause of cancer-related death. Surgery is followed by adjuvant chemo-therapy with either single agent capecitabine or a mixture therapy, chemotherapy toxicity might damage a cancer patients quality of life and lead to treatment cessation early. Hematological, gastrointestinal, constitutional, dermatological, and neurological toxicity are all common.
Aim of the Work: To measure and evaluate chemotherapy toxicity in Colon patients undergoing adjuvant and metastatic treatment.
Patients and Methods: This was retrospective stud y involved 158 cases of colon cancer established adjuvant and palliative chemotherapy and at Clinical Oncology Department, El Hussein Hospital during the period from 2012 till 2018
Results: We discovered that neurological toxicity is the most commonly reported side effect of chemotherapy, that older patients have a higher incidence of neurological toxicity and fatigue, that females have a higher incidence of anemia (increased Oxaliplatin cumulative dose increases the incidence of neurological toxicity, thrombocytopenia) and renal toxicity, and that older patients have a higher incidence of anemia (increased Oxaliplatin cumulative dose increases the incidence of neurological toxicity, thrombocytopenia) Oxaliplatin-containing regimens have a strong link to neurological toxicity, while capecitabine-containing regimens have a strong link to dermatological damage.
Conclusion: Neurological damage was the most common hazard documented with adjuvant treatment for CRC. Despite the fact that a variety of side effects were identified, the treatment regimes were well accepted, we should be aware of factors that could increase toxicity.